Prostate cancer: PARP inhibitors in prostate cancer

December 06, 2023 00:26:43
Prostate cancer: PARP inhibitors in prostate cancer
COR2ED - Oncology Medical Conversation
Prostate cancer: PARP inhibitors in prostate cancer

Dec 06 2023 | 00:26:43

/

Show Notes

COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia Morgans, Genitourinary Medical Oncologist and Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute in the United States, discuss 'PARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patientsas part of the GU NURSES CONNECT podcast series covering PARP inhibitors in prostate cancer’.

In this podcast, the experts discuss adverse events associated with PARP inhibitors and the management of them, in particular thrombocytopenia, gastrointestinal effects and fatigue. Jason provides some insight into how nurses support and communicate with patients, the importance of early reporting of side effects and how to manage these. Finally, the ongoing trials of PARP inhibitors in combination with other prostate cancer treatments are also considered and what these trials may mean for patients.

Other Episodes

Episode

January 10, 2024 00:31:12
Episode Cover

Treatment optimization in mCRC: third-line and beyond

Treatment of advanced colorectal cancer should be considered a continuum of care and patients should be offered as many life prolonging therapies as possible. ...

Listen

Episode

September 11, 2024 00:29:55
Episode Cover

Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey

In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins...

Listen

Episode

November 08, 2024 00:25:50
Episode Cover

BRAF-mutated CRC: testing to treatment

Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available...

Listen